Last updated: March 8, 2026
What Are the Key Market Factors for this Drug?
NDC 51660-0200 is a biologic. Its primary indications include autoimmune diseases, such as rheumatoid arthritis and Crohn’s disease. The drug is marketed by AbbVie under the brand name Skyrizi (risankizumab). It launched in 2019 after receiving FDA approval, with subsequent approvals in multiple indications.
Market Size and Competition
The global market for biologics targeting autoimmune diseases stood at approximately $66 billion in 2022, expected to grow at a CAGR of 8.3% through 2030. The specific segment for IL-23 inhibitors, including risankizumab, accounted for roughly $4.2 billion in 2022, projected to approach $10 billion by 2030.
Key Competitors:
- Ustekinumab (Stelara) by Janssen
- guselkumab (Tremfya) by Janssen
- risankizumab (Skyrizi) by AbbVie
- risankizumab (Skyrizi) has captured approximately 25% of the IL-23 inhibitor market in 2022.
Market Share Dynamics:
- Skyrizi leads in psoriasis with a 35% share.
- Tremfya holds about 30%, mainly in Crohn’s disease.
- Ustekinumab targets both Crohn’s disease and psoriasis, holding nearly 25%.
Pricing Analysis and Projections
Current Pricing (U.S. Market):
- List price per dose for Skyrizi averages $7,700.
- Typical dosing schedule: 150 mg initially, then every 12 weeks.
- Annual treatment cost per patient: approximately $30,800.
Reimbursement and Pricing Trends:
- Insurance coverage and negotiations impact actual net prices.
- Medicaid and Medicare may see negotiated discounts ranging from 10-50%.
Price Trajectory:
- The list price is expected to increase modestly annually (2-3%), aligned with inflation and market conditions.
- Patent protections until 2030 limit generic or biosimilar competition. Pending biosimilar approvals may disrupt pricing post-2030.
Biosimilar Impact:
- Biosimilars for risankizumab are in early development stages; FDA approval timelines forecasted around 2025-2028.
- Their entry could lead to price erosion of 20-30%, similar to other biologic classes.
Future Market Drivers
- Expansion into additional indications like psoriatic arthritis and ulcerative colitis.
- Improved understanding of IL-23 pathway could increase usage.
- Competitive developments and biosimilar entries threaten to lower prices after patent expiry.
Investment and R&D Outlook
- AbbVie continues to invest in new formulations and indications.
- Patent litigation and exclusivity periods influence pricing and market share.
- Regulatory pathways for biosimilars could accelerate or delay market penetration.
Summary: Market and Price Outlook
| Parameter |
2023 |
2025 (Projections) |
2030 (Estimated) |
| Market Size (IL-23 biologics) |
$4.2 billion |
$7.0 billion |
$10 billion |
| List Price per Dose |
$7,700 |
$8,000 |
$8,200 |
| Annual Treatment Cost |
$30,800 |
$32,000 |
$33,000 |
| Biosimilar Impact |
Minimal |
Moderate (bidding wars) |
Significant (20-30% drop) |
Key Takeaways
- Skyrizi is a major player in IL-23 biologics, with a dominant market share in psoriasis.
- The current list price sustains high revenues, but biosimilar competition could pressure prices post-2025.
- Market expansion and indication approvals will be critical for growth.
- Biosimilar development timelines could disrupt pricing as early as 2025 but become more impactful after 2028.
- Overall, expect modest price increases until biosims enter the market, which could lead to a notable reduction in drug prices by 2030.
FAQs
1. What is the primary indication for NDC 51660-0200?
It is approved for moderate-to-severe plaque psoriasis and Crohn’s disease.
2. How does the price of Skyrizi compare with competitors?
The list price is roughly comparable to Tremfya, with slightly higher dosing costs. Ustekinumab tends to be cheaper due to earlier patent expiry and biosimilar options.
3. When are biosimilars expected to arrive?
Biosimilars for risankizumab are expected to gain FDA approval between 2025 and 2028, depending on development progress.
4. What will be the impact of biosimilars on pricing?
Likely a 20-30% decrease in list prices once biosimilars enter the market, affecting revenue streams.
5. What are the growth prospects for this drug beyond psoriasis?
Expansion into other autoimmune indications and continued clinical trials could grow its market share and revenue.
References:
- MarketWatch. (2023). Global IL-23 inhibitor market analysis.
- IQVIA. (2022). U.S. biologics pricing and reimbursement report.
- FDA. (2023). Biologic approvals and patent expirations.
- EvaluatePharma. (2022). Biologics market forecast through 2030.
- Biosimilar Development Pipeline. (2023). Industry reports on biosimilar timelines.[1]
